Business Context and Reporting Period
Company: Silo Pharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 26, 2024
Reporting Period: Event date June 26, 2024; Signed June 27, 2024
Silo Pharma, Inc., a Nevada corporation, reported the entry into a material definitive agreement involving its wholly-owned subsidiary, Silo Pharma, Inc. (Florida corporation).
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
Item 1.01 - Entry into a Material Definitive Agreement:
- Counterparty: University of Maryland, Baltimore.
- Agreement: Fourth Amendment to Master License Agreement.
- Key Change: The parties agreed to an amended and restated schedule of diligence milestones for the Master License Agreement.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the description of the Fourth Amendment is not complete and is qualified in its entirety by reference to the full agreement attached as Exhibit 10.1.
Risks and Contingencies: No specific risks, contingencies, or unusual items are detailed in the body of this report beyond the standard qualification regarding the attached exhibit.
Guidance: No financial guidance or outlook is provided in this filing.
Investor Verification Checklist
- Review Exhibit 10.1 (Fourth Amendment to Master License Agreement) to understand the specific amended diligence milestones.
- Verify the impact of the new milestone schedule on the company's operational timeline and potential future funding requirements.
- Confirm the status of the Master License Agreement with the University of Maryland, Baltimore, to assess any prior performance against previous milestones.